Customize in-house access of data for analyses with public and internal datasets for immediate insights to inform your translational and clinical development teams.
Our specialized team works with you to develop the informatics tools and evidence resources you need to get consistent, reliable, and actionable results through all phases of your study.
Develop informatics tools and evidence resources
With QIAGEN RWI, you can use real-world data to:
Analyze the prevalence of co-occurring biomarkers
Understand the molecular profiles of a real-world population
Incorporate a quality-managed database into your CDx workflow to classify novel variants identified by the diagnostic assay
Associate genomic and diagnostic profiles to support reimbursement plans
Design a project targeting rare cancer types
QIAGEN is helping to take cancer drug development to the next level by aligning the real-world data and comprehensive analyses needed to support biomarker and indication selection for trial stratification and CDx labeling with the superior technical design, regulatory expertise, and manufacturing excellence that are required to deliver the precision CDx that will identify the patients who will derive the most benefit from the targeted therapies.
Sheryl Elkin, Ph.D., Chief Scientific Officer at N-of-One, a QIAGEN company
Leverage Real-World Insights
QIAGEN’s RWI portfolio combines robust real-world genomic data from over 200,000 cancer cases and advanced analytics to achieve better decisions faster in early drug and test development.
To access RWI, you can:
Receive data analyses in full reports with accompanying graphics
Access data in-house via industry standard tools (e.g., cBioPortal instance)
Do you have novel questions, hypotheses, and hurdles to overcome? Our team of scientists, bioinformaticists, and clinicians can help you strategize, customize, and deliver within your timeline.